Functional evidence for two distinct mechanisms of action of progesterone and selective progesterone receptor modulator on uterine leiomyomas

被引:3
|
作者
Milewska, Gabriela
Ponikwicka-Tyszko, Donata [1 ]
Bernaczyk, Piotr [2 ]
Lupu, Oana
Szamatowicz, Michal
Sztachelska, Maria [1 ]
Pilaszewicz-Puza, Agata [2 ]
Koda, Mariusz [3 ]
Bielawski, Tomasz [1 ]
Zbucka-Kretowska, Monika
Pawelczyk, Adam [4 ]
Tomaszewski, Jakub [5 ]
Li, Xiangdong [6 ]
Huhtaniemi, Ilpo [1 ,7 ,8 ]
Wolczynski, Slawomir [1 ]
Rahman, Nafis A. [9 ]
机构
[1] Med Univ Bialystok, Dept Reprod & Gynecol Endocrinol, Bialystok, Poland
[2] Polish Acad Sci, Inst Anim Reprod & Food Res, Dept Biol & Pathol Human Reprod, Olsztyn, Poland
[3] Med Univ Bialystok, Dept Med Pathomorphol, Bialystok, Poland
[4] Med Univ Bialystok, Dept Gen Pathomorphol, Bialystok, Poland
[5] Poznan Univ Med Sci, Dept Gen Vasc & Transplant Surg, Div Gen & Transplant Surg, Poznan, Poland
[6] Tomaszewski Med Ctr Obstet & Gynecol, Bialystok, Poland
[7] China Agr Univ, State Key Lab Agrobiotechnol, Beijing, Peoples R China
[8] Imperial Coll London, Inst Reprod & Dev Biol, Dept Metab Digest & Reprod, London, England
[9] Univ Turku, Inst Biomed, Turku 20520, Finland
基金
芬兰科学院;
关键词
Leiomyoma; progesterone; selective progesterone receptor modulator; extracellular matrix; growth factors; COLLAGEN MESSENGER-RNA; P38; MAPK; BETA; PATHOGENESIS; PATHWAYS; FIBRONECTIN; EXPRESSION; TARGET;
D O I
10.1016/j.fertnstert.2024.02.046
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To study the specific fi c mechanisms through which progesterone and selective progesterone receptor modulators impact the growth, synthesis, and accumulation of the extracellular matrix in uterine leiomyomas. Design: Laboratory study. Setting: Academic Research Institutions. Patients (s): This study involved reproductive-age women diagnosed with infertility associated uterine leiomyomas who underwent myomectomy either after selective progesterone receptor modulator ulipristal acetate (UA) treatment or without any pharmacological pretreatment. Control samples included healthy myometrium tissue (n = 100). Specimens were obtained from the Department of Reproduction and Gynecological Endocrinology and Biobank, Medical University of Bialystok, Poland. Interventions: Daily (5 mg/d) UA treated for 2 months (n = 100) and untreated (n = 150) patients with uterine leiomyomas or normal healthy myometrium (n = 100) tissue samples immediately after surgery were collected for transcriptional analysis and assessments. Main Outcome Measures: Progesterone-induced activation of the signaling pathways related to uterine leiomyomas extracellular matrix synthesis, deposition, and growth, as well as the expression profile fi le of progesterone receptors in uterine leiomyomas, were assessed. Results: The results indicated that progesterone activated the transforming growth factor-f3 f3 and SMAD3 signaling pathways and promoted proliferation, growth, and extracellular matrix remodeling in uterine leiomyomas by up-regulating SMAD3, transforming growth factor-f3 f3 (TGF-f3) f3 ) receptor type 1 and II, Ras homolog A, vascular endothelial growth factor, or increasing the fi brosis- related gene collagen, type I, alpha-1, and procollagen, type I, alpha-1 production. In contrast, UA had inhibitory effects on these processes. The study also showed that both nuclear and membrane progesterone receptors play distinct roles in uterine leiomyoma pathobiology. Conclusions: We showed that both nuclear and membrane progesterone receptors were relevant in the treatment of uterine leiomyomas, especially when combined with selective progesterone receptor modulators. Novel therapeutic approaches combining selective progesterone receptor modulators with or without direct and indirect extracellular matrix targeting through selected specifically fi cally TGF-3 3 and SMAD3 (SMAD3, TGF-3 3 receptor types 1 and II, Ras homolog A, vascular endothelial growth factor, collagen, type I,alpha-1) alpha-1) signaling pathways could therefore be a treatment option for uterine leiomyomas. (Fertil Steril (R) (R) 2024;122:341-51. - 51. (c) 2024 by American Society for Reproductive Medicine.) El resumen est & aacute; disponible en Espa & ntilde;ol al final del art & iacute;culo.
引用
收藏
页码:341 / 351
页数:11
相关论文
共 50 条
  • [1] Action of progesterone receptor modulators on uterine leiomyomas
    Ohara, N.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2008, 35 (03): : 165 - 166
  • [2] Selective Progesterone Receptor Modulators for the Treatment of Uterine Leiomyomas
    Safrai, Myriam
    Chill, Henry H.
    Salzman, Adi Reuveni
    Shushan, Asher
    OBSTETRICS AND GYNECOLOGY, 2017, 130 (02): : 315 - 318
  • [3] Progesterone and progesterone receptor modulator in uterine leiomyoma growth
    Maruo, Takeshi
    GYNECOLOGICAL ENDOCRINOLOGY, 2007, 23 (04) : 186 - 187
  • [4] Progesterone Action in Endometrial Cancer and Uterine Leiomyomas.
    Kim, J. Julie
    Ward, Erin C.
    Sefton, Elizabeth C.
    Lu, Zhenxiao
    BIOLOGY OF REPRODUCTION, 2009, : 63 - 63
  • [5] Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications
    Chabbert-Buffet, N
    Meduri, G
    Bouchard, P
    Spitz, IM
    HUMAN REPRODUCTION UPDATE, 2005, 11 (03) : 293 - 307
  • [6] Asoprisnil -: Endometriosis therapy treatment of uterine fibroids selective progesterone receptor modulator
    Cole, P
    Castañer, J
    Fernández-Forner, D
    DRUGS OF THE FUTURE, 2005, 30 (10) : 985 - 991
  • [7] Pretreatment of Uterine Fibroids Using a Selective Progesterone Receptor Modulator - Ulipristal Acetate
    Thompson, M.
    Wong, M.
    Opemuyi, I.
    Madipola, N.
    Ramadan, T.
    Nnochiri, A.
    Guttman, J.
    20TH WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY (COGI), 2015, : 205 - 210
  • [8] Effect of a Selective Progesterone Receptor Modulator on Induction of Apoptosis in Uterine Fibroids In Vivo
    Horak, Petr
    Mara, Michal
    Dundr, Pavel
    Kubinova, Kristyna
    Kuzel, David
    Hudecek, Robert
    Chmel, Roman
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2012, 2012
  • [9] Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate
    Donnez, Jacques
    Donnez, Olivier
    Dolmans, Marie-Madeleine
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (12) : 1679 - 1686
  • [10] Vilaprisan Progesterone receptor modulator Treatment of uterine fibroids
    Barra, F.
    Seca, M.
    Ferrero, S.
    DRUGS OF THE FUTURE, 2019, 44 (03) : 211 - 219